SAGE
SAGE Therapeutics Inc
Price:  
11.78 
USD
Volume:  
770,833.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

SAGE EV/EBITDA

-1353.3%
Upside

As of 2024-05-27, the EV/EBITDA ratio of SAGE Therapeutics Inc (SAGE) is -1.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. SAGE's latest enterprise value is 536.27 mil USD. SAGE's TTM EBITDA according to its financial statements is -507.44 mil USD. Dividing these 2 quantities gives us the above SAGE EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 13.1x - 16.7x 14.1x
Forward P/E multiples 19.3x - 22.7x 21.6x
Fair Price (160.04) - (138.28) (147.64)
Upside -1458.6% - -1273.9% -1353.3%
11.78 USD
Stock Price
(147.64) USD
Fair Price

SAGE EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2024-05-24 -1.06
2024-05-23 -1.00
2024-05-22 -1.09
2024-05-21 -1.09
2024-05-20 -0.99
2024-05-17 -1.05
2024-05-16 -1.08
2024-05-15 -1.05
2024-05-14 -1.08
2024-05-13 -1.10
2024-05-10 -1.07
2024-05-09 -1.12
2024-05-08 -1.13
2024-05-07 -1.20
2024-05-06 -1.23
2024-05-03 -1.31
2024-05-02 -1.21
2024-05-01 -1.23
2024-04-30 -1.31
2024-04-29 -1.34
2024-04-26 -1.28
2024-04-25 -1.27
2024-04-24 -1.32
2024-04-23 -1.20
2024-04-22 -1.19
2024-04-19 -1.24
2024-04-18 -1.21
2024-04-17 -1.15
2024-04-16 -1.51
2024-04-15 -1.48
2024-04-12 -1.49
2024-04-11 -1.62
2024-04-10 -1.61
2024-04-09 -1.62
2024-04-08 -1.63
2024-04-05 -1.61
2024-04-04 -1.63
2024-04-03 -1.69
2024-04-02 -1.71
2024-04-01 -1.78
2024-03-28 -1.88
2024-03-27 -1.92
2024-03-26 -1.87
2024-03-25 -1.88
2024-03-22 -1.94
2024-03-21 -2.03
2024-03-20 -1.99
2024-03-19 -1.95
2024-03-18 -1.96
2024-03-15 -2.03